

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): March 2, 2017**

---

**pSivida Corp.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-51122**  
(Commission  
File Number)

**26-2774444**  
(IRS Employer  
Identification No.)

**480 Pleasant Street**  
**Watertown, MA**  
(Address of principal executive offices)

**02472**  
(Zip Code)

Registrant's telephone number, including area code: **(617) 926-5000**

(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**Item 8.01. Other Events.**

On March 2, 2017, pSivida Corp. (the “Company”) entered into a funded feasibility study agreement with a leading biopharmaceutical company. Under phase one of the work plan, the Company’s proprietary Durasert™ sustained release drug technology will be formulated with certain of the biopharmaceutical company’s proprietary molecules to determine potential pre-clinical benefits. Pending results of the formulation research, the biopharmaceutical company may elect to proceed with phase two of the pre-clinical work plan, which will involve combining Durasert with one or more of the proprietary molecules evaluated in phase one of the feasibility study agreement.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**pSivida Corp.**

Date: March 6, 2017

By:           /s/ Nancy Lurker          

Name: Nancy Lurker

Title: President and Chief Executive Officer